CTC report Bronwen Shaw – chair Andy Peniket – secretary

CTC operations Meet 3/year: next meeting 14 th November BSH House New processes working well – Each meeting preceded in am by ‘PI’ meeting for specific studies (PI plus office staff). Many PIs have taken advantage of this – Regular teleconferences – review progress of each study, invite specific PIs Letter of understanding for PIs

CTC activity: manuscripts Published – GvL in ALL (Medd et al) – outcomes in severe autoimmune disease (Snowden et al) – results of RIC allos for mantle cell lymphoma (Cook et al) – a comparison of ATG vs Alemtuzumab based conditioning in aplastic anaemia (Marsh et al) Preparation/submitted – second allogeneic transplants (Lown et al) – impact of KIR on AML transplant outcomes (Schellekens et al) – pulmonary function post allograft (brown et al) – BEAM-campath for lymphoproliferative disorders (Fox et al) – refractory myeloma (Cook et al) – impact of pre-transplant campath in CLL (Protheroe et al) – Allo SCT in elderly patients (Nikolousis/Craddock et al) – Cord blood retrospective analysis (Snowden/Rocha et al) – joint study with Eurocord Analysis: Impact of HLA matching on survival (Shaw et al)

CTC activity: supporting ongoing prospective studies The FIGARO study for high risk AML has just opened (Craddock) Myeloma X (Cook) National cord blood studies (Hough) and immune reconstitution Hodgkin’s study (Peggs) MCL study (Rule) Haplo-identical transplant protocols (Raj/Mackinnon/Pagliuca) Prospective data collection studies co-morbidities (Gilleece) intracranial haemorrhage (Stanworth)

CTC activity: new proposals In development – mesenchymal stromal cells (Dazzi) – invariant NKT cells (Karadimitris) – Myelofibrosis trial (Mead/Gilleece) New projects: – paediatric refractory AML (O’Hare) – incidence and risks or TTP (Hill) – second line treatments for acute GvHD (Das Gupta) Surveys: – Late effects (Snowden) – EBV monitoring (Hamblin)